연구성과로 돌아가기

2023 연구자 정보 (464 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Kim, Kwang-Kuk
(Kim, KK) ⓘ 		Univ Ulsan, Asan Med Ctr, Dept Neurol, Coll Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis ⓘ SCIE ⓘ 13.4 CLINICAL NEUROLOGY ⓘ paddy.waters@ndcn.ox.ac.uk;nrhong@gmail.com; ⓘ
Kim, Nam-Hee
(Kim, NH) ⓘ 		Dongguk Univ, Dept Neurol, Ilsan Hosp, Goyang, South Korea ⓘ B-9921-2013
Kim, Tae ⓘ
ⓘ 		[JCR상위 13.4] Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis ⓘ SCIE ⓘ 13.4 CLINICAL NEUROLOGY ⓘ paddy.waters@ndcn.ox.ac.uk;nrhong@gmail.com; ⓘ
Kim, Sung Min
(Kim, SM) ⓘ 		Seoul Natl Univ, Coll Med, Dept Neurol, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum ⓘ SCIE ⓘ 13.4 CLINICAL NEUROLOGY;NEUROSCIENCES ⓘ ⓘ
Kim, Youngho
(Kim, Y) ⓘ 		제1저자 Kyungpook Natl Univ Hosp, Neurol, Daegu, South Korea
Kyungpook Natl Univ Hosp, Dept Neurol, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] A Case of Neuromyelitis Optica Spectrum Disorder and Infectious Polyradiculitis after BNT161b2 Vaccination and SARS-CoV-2 Infection
[JCR상위 98.4] Centronuclear myopathy with a novel variant (p.Asp646Tyr) in the DNM2 gene exhibits mild clinical manifestations: A case report ⓘ 		SCIE ⓘ 13.4 CLINICAL NEUROLOGY;NEUROSCIENCES
CLINICAL NEUROLOGY ⓘ 		azulmar@gmail.com; ⓘ
Kwon, Ki-Han
(Kwon, KH) ⓘ 		Hallym Univ, Coll Med, Dept Neurol, Dongtan Sacred Heart Hosp, Hwaseong, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis ⓘ SCIE ⓘ 13.4 CLINICAL NEUROLOGY ⓘ paddy.waters@ndcn.ox.ac.uk;nrhong@gmail.com; ⓘ
Kwon, Ohyun
(Kwon, O) ⓘ 		Eulji Univ, Uijeongbu Eulji Med Ctr, Dept Neurol, Sch Med, Uijongbu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis ⓘ SCIE ⓘ 13.4 CLINICAL NEUROLOGY ⓘ paddy.waters@ndcn.ox.ac.uk;nrhong@gmail.com; ⓘ
Lee, Jeong-Seok
(Lee, JS) ⓘ 		Baobab Healthcare Inc, Res Inst Addit Mfg & Regenerat Med, Ansan 15588, Gyeonggi Do, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] FeS2-incorporated 3D PCL scaffold improves new bone formation and neovascularization in a rat calvarial defect model ⓘ SCIE ⓘ 13.4 ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS ⓘ ash4235@kmedihub.re.kr;hojun@baobabhcare.com; ⓘ
Lee, Jong-Mok
(Lee, JM) ⓘ 		Kyungpook Natl Univ Hosp, Neurol, Daegu, South Korea
Kyungpook Natl Univ Hosp, Dept Neurol, Daegu, South Korea
Kyungpook Natl Univ, Sch Med, Dept Neurol, 680 Gukchaebosang Ro, Daegu 41944, South Korea
Kyungpook Natl Univ, Sch Med, Daegu, South Korea
Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Neurol, Daegu, South Korea ⓘ 		KVY-9550-2024
Lee, Jong-Mok ⓘ 		0000-0002-2918-6166
Lee, Jong-Mok ⓘ 		[JCR상위 13.4] A Case of Neuromyelitis Optica Spectrum Disorder and Infectious Polyradiculitis after BNT161b2 Vaccination and SARS-CoV-2 Infection
[JCR상위 98.4] Centronuclear myopathy with a novel variant (p.Asp646Tyr) in the DNM2 gene exhibits mild clinical manifestations: A case report
[JCR상위 38.7] Impact of nusinersen on the health-related quality of life and caregiver burden of patients with spinal muscular atrophy with symptom onset after age 6 months
[JCR상위 1.5] Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum
[JCR상위 13.4] Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum ⓘ 		SCIE ⓘ 1.5 CLINICAL NEUROLOGY;NEUROSCIENCES
CLINICAL NEUROLOGY
CLINICAL NEUROLOGY;PSYCHIATRY;SURGERY ⓘ 		azulmar@gmail.com;
shkwon@knu.ac.kr;chaeped1@snu.ac.kr;
bjkim@skku.edu;sueh916@gmail.com; ⓘ
Lee, KyoungHo
(Lee, K) ⓘ 		Daegu Gyeongbuk Med Innovat Fdn K MEDI Hub, Preclin Res Ctr, Daegu 41061, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] FeS2-incorporated 3D PCL scaffold improves new bone formation and neovascularization in a rat calvarial defect model ⓘ SCIE ⓘ 13.4 ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS ⓘ ash4235@kmedihub.re.kr;hojun@baobabhcare.com; ⓘ
Lee, SangGon
(Lee, S) ⓘ 		Hanyang Univ, Coll Med, Dept Neurol, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum ⓘ SCIE ⓘ 13.4 CLINICAL NEUROLOGY;NEUROSCIENCES ⓘ ⓘ
Lee, Yoon Bum
(Lee, YB) ⓘ 		Daegu Gyeongbuk Med Innovat Fdn K MEDI Hub, Preclin Res Ctr, Daegu 41061, South Korea ⓘ
ⓘ 		0000-0002-5469-1439
lee, yoonbeom ⓘ 		[JCR상위 13.4] FeS2-incorporated 3D PCL scaffold improves new bone formation and neovascularization in a rat calvarial defect model ⓘ SCIE ⓘ 13.4 ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS ⓘ ash4235@kmedihub.re.kr;hojun@baobabhcare.com; ⓘ
Lim, Young-Min
(Lim, YM) ⓘ 		Univ Ulsan, Asan Med Ctr, Dept Neurol, Coll Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis ⓘ SCIE ⓘ 13.4 CLINICAL NEUROLOGY ⓘ paddy.waters@ndcn.ox.ac.uk;nrhong@gmail.com; ⓘ
Nam, Yoonju
(Nam, Y) ⓘ 		Baobab Healthcare Inc, Res Inst Addit Mfg & Regenerat Med, Ansan 15588, Gyeonggi Do, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] FeS2-incorporated 3D PCL scaffold improves new bone formation and neovascularization in a rat calvarial defect model ⓘ SCIE ⓘ 13.4 ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS ⓘ ash4235@kmedihub.re.kr;hojun@baobabhcare.com; ⓘ
Oh, JeeYoung
(Oh, J) ⓘ 		Konkuk Univ, Sch Med, Dept Neurol, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum ⓘ SCIE ⓘ 13.4 CLINICAL NEUROLOGY;NEUROSCIENCES ⓘ ⓘ
Park, Hyung Jun
(Park, HJ) ⓘ 		Yonsei Univ, Gangnam Severance Hosp, Dept Neurol, Coll Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 13.4] Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis ⓘ SCIE ⓘ 13.4 CLINICAL NEUROLOGY ⓘ paddy.waters@ndcn.ox.ac.uk;nrhong@gmail.com; ⓘ
페이지 이동: